期刊
SEMINARS IN CANCER BIOLOGY
卷 72, 期 -, 页码 90-101出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2020.05.019
关键词
Breast cancer; TILs; Immune checkpoint; ACT; CAR-T
类别
资金
- Fondazione Umberto Veronesi postdoctoral fellowships
Cancer immunotherapy has shown promising results in various types of cancer, including breast cancer. Current research focuses on using T cells as markers for clinical practice and therapeutic options in breast cancer treatment to expand the application of immunotherapy.
Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据